Am J Transplant, Volume 18, Suppl 3 Archives - Page 67 of 211 - ATC Abstracts

2018 American Transplant Congress
Donor-Specific B-Cell Tolerance after Successful ABO Blood Type Incompatible (ABOi) Living Donor Liver Transplantation (LDLT)
T-.J. Wu, Y-.C. Wang, C-.H. Cheng, T-.H. Wu, C-.F. Lee, H. Chou, K-.M. Chan, W-.C. Lee.
Division of Liver and Transplantation Surgery, Department of General Surgery, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.
Background/purposeABO blood type-incompatible (ABOi) liver transplantation is one of the strategies employed to overcome the shortage of donor. By using the Rituximab and plasm exchange,…
2018 American Transplant Congress
Increase in Potentially Resistant Non-Aspergillus Molds Isolated in Lung Transplant Recipients after Voriconazole and Posaconazole Prophylaxis
M. Fung,¹ J. Greenland,^2,3 S. Hays,² J. Singer,² J. Golden,² P. Chin-Hong.¹
¹Infectious Diseases, University of California San Francisco, San Francisco, CA; ²Pulmonary and Critical Care, University of California San Francisco, San Francisco, CA.
Background: Lung transplant recipients are at higher risk for invasive fungal infections compared to other solid organs transplant patients. Antifungal prophylaxis with mold-active azoles has…
2018 American Transplant Congress
Genetically Modified Porcine Erythrocytes: A Cell Model for Studying Human Preformed Antibody-Dependent Xenoimmune Responses In Vitro
Z. Wang, G. Martens, J. Ladowski, M. Tector, A. Tector.
Surgery, University of Alabama at Birmingham, Birmingham, AL.
Background: Powerful gene editing technology is a promising approach to provide genetically-modified pigs as donors for clinical cell, tissue and organ xenotransplantation. Prior to starting…
2018 American Transplant Congress
Transplanting Kidneys from HCV-Infected Donors into HCV-Negative Recipients: Longer-Term and Extended Results of the THINKER Trial
D. Goldberg,¹ E. Blumberg,¹ P. Abt,¹ M. Levine,¹ P. Porrett,¹ A. Naji,¹ S. Nazarian,¹ D. Sawinski,¹ J. Trofe-Clark,¹ V. Van Deerlin,¹ C. Gentile,¹ J. Smith,¹ M. Kaminski,¹ A. Sicilia,¹ R. Hasz,² L. Suplee,² R. Reddy,¹ R. Bloom,¹ P. Reese.¹
¹University of Pennsylvania, Philadelphia; ²Gift of Life, Philadelphia.
Background: In 2016, 800 kidneys from HCV+ deceased donors were discarded. Short-term (6-month) data from the first 10 subjects in the THINKER-1 trial (NCT02743897; funder:…
2018 American Transplant Congress
Outcome Implications of Benzodiazepines and Opioid Co-Prescriptions before Kidney Transplantation
N. Lam,¹ M. Schnitzler,² D. Axelrod,³ V. Dharnidharka,⁴ D. Segev,⁵ A. Naik,⁶ H. Xiao,² R. Ouseph,² H. Randall,² G. Hess,⁷ B. Kasiske,⁸ D. Brennan,⁵ T. Alhamad,⁴ K. Lentine.²
¹Univ Alberta, Edmonton, Canada; ²Saint Louis Univ, St. Louis; ³Lahey Clinic, Burlington; ⁴Washington Univ, St. Louis; ⁵Johns Hopkins, Baltimore; ⁶Univ Michigan, Ann Arbor; ⁷Hennepin, Minneapolis; ⁸Symphony Health, Conshohocken.
Recent studies have identified co-prescription of benzodiazepines and opioids as a risk factor for adverse outcomes in the general population. We previously described associations of…
2018 American Transplant Congress
ACEI/ARB Use within One Year of Kidney Transplant is Associated with Less AKI and Graft Loss in Older Recipients
M. Posadas Salas, R. Rodriguez, P. Amaechi, V. Rao, D. Taber.
Medical University of South Carolina, Charleston, SC.
As short-term outcomes have improved, optimizing long-term graft survival remains a major focus of transplant programs. Older kidney transplant recipients are particularly vulnerable to acute…
2018 American Transplant Congress
The Impact of Early versus Late Clinical Outcomes on Disparities in African-American Kidney Transplant Recipients
D. Taber, J. Fleming, Z. Su, P. Mauldin, J. McGillicuddy, S. Nadig, V. Rohan, P. Baliga, D. Dubay.
MUSC, Charleston, SC.
Background: It is important to better understand the impact of early and late clinical events on disparities in African-American (AA) kidney transplant (KTX), which will…
2018 American Transplant Congress
Donor Bone Marrow CXCR4+ Foxp3+ Treg Cells Are Essential for Costimulation Blockade-Induced Long-Term Survival of Murine Limb Transplants
L. Wang,¹ Z. Wang,¹ R. Han,¹ G. Ge,¹ L. Levin,² M. Levine,² W. Hancock.^1,2
¹CHOP, Philadelphia; ²UPenn, Philadelphia.
Vascularized composite allotransplantation (VCA) would likely be more widely performed if maintenance immunosuppression was not essential for graft acceptance. Accordingly, we used murine models of…
2018 American Transplant Congress
Improving DCD Livers Graft Function Using CD47 Blockade in the Setting of Normothermic Liver Perfusion
S. Garcia-Aroz,¹ M. Xu,¹ X. Wang,¹ J. Hollingshead,¹ A. Khan,¹ B. Banan,¹ L. Kang,² Z. Zhang,¹ G. Upadhya,¹ Y. Lin,¹ P. Manning,³ W. Chapman.¹
¹Surgery, Washington University, St. Louis; ²Pathology, Washington University, St. Louis; ³Arch Oncology, St. Louis.
Background: Towards the goal of utilizing more livers for transplantation, transplant centers are looking to increase the use of organs from marginal donors. Livers from…
2018 American Transplant Congress
Extended Experience Using Tocilizumab (Anti-IL6R, TCZ) for the Treatment of Chronic Antibody Mediated Rejection (CABMR)
J. Choi,¹ O. Aubert,² S. Louie,¹ N. Ammerman,¹ A. Vo,¹ A. Peng,¹ E. Huang,¹ R. Najjar,¹ D. Puliyanda,¹ S. Sethi,¹ M. Haas,¹ K. Lim,¹ A. Loupy,² S. Jordan.¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Paris Translational Center for Organ Transplantation, Paris, France.
Introduction: Disruption of the IL-6/IL-6R pathways may have benefits in treating allograft rejection. We reported our experience with anti-IL-6R (TCZ) as a treatment for CABMR…